SynAct Pharma AB (SYNACT) — Strategic Asset Allocation Index

Latest as of June 2023: 0.4%

SynAct Pharma AB (SYNACT) has a Strategic Asset Allocation Index of 0.4% as of June 2023. Strategic assets (PP&E of Skr993.00K plus long-term investments of Skr-) total Skr993.00K, measured against net assets of Skr241.50 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See SYNACT net asset quality score to measure how much of total assets are equity-financed.

SAAI

0.4%
Strategic Assets / Net Assets

Strategic Assets

Skr993.00K
PP&E + LT Investments

PP&E

Skr993.00K
SEK

Net Assets

Skr241.50 Million
SEK

SynAct Pharma AB Strategic Asset Allocation Index (2021–2022)

This chart shows how SynAct Pharma AB's Strategic Asset Allocation Index has evolved across 2 annual periods from 2021 to 2022. As of June 2023, the index stands at 0.4%, representing strategic assets of Skr993.00K against net assets of Skr241.50 Million SEK. For live market cap and overall valuation, see SynAct Pharma AB market capitalisation.

Annual Strategic Asset Allocation Index for SynAct Pharma AB (2021–2022)

The table below presents the year-by-year Strategic Asset Allocation Index for SynAct Pharma AB from 2021 to 2022, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See SYNACT total equity for net asset value and shareholders' equity analysis.

Year SAAI Strategic Assets (SEK) PP&E LT Investments Net Assets Change (pp)
2022 1.7% Skr2.10 Million Skr2.10 Million Skr- Skr126.52 Million ▼ -13.6 pp
2021 15.2% Skr3.18 Million Skr3.18 Million Skr- Skr20.87 Million
pp = percentage points